Amarin Corp Plc (AMRN)

[dogn]

Great new Alex Denner interview by Cowen:

https://www.cowen.com/insights/unlocking-value-from-the-inside/

Alex Denner:

Because we don’t actively try to sell it. We’re just open to selling it if it’s above our risk adjusted assessments as to the value. And when the risk becomes lower, in other words, after we fix some of the underlying problems, the risk is lower to a pharma company, which are very risk averse buyers, right? The buyers in healthcare are very risk averse. They don’t want to buy messy things by and large. They want things that are all clean and nice. They might even overpay a little from the perspective of the owner of the business, because there are other strategic implications for them. For instance, if you sell a cardiovascular or let’s say a cardiology product to a company that’s already in cardiology, the incremental cost of selling a new drug may be the cost of the brochures for the one drug.